Clinical Efficacy of Bevacizumab Combined with Paclitaxel and Cisplatin Based Synchronous Radio-chemotherapy in the Treatment of Cervical Cancer
[Objective]To investigate the efficacy of bevacizumab combined with paclitaxel+cisplatin(TP)based synchronous radiochemotherapy in the treatment of cervical cancer.[Methods]Ninety cervical cancer patients admitted to our hospital from December 2021 to January 2023 were selected and randomly divided into the observation group and the control group using a random number table method,with 45 patients in each group.The control group was treated with TP synchronous radiotherapy and chemotherapy,while the observation group was treated with bevacizumab on the basis of the control group.One treatment cycle was 21 days,and both groups were treated for three cycles.Two groups were compared in terms of clinical efficacy,serological indicators,immune function indicators,quality of life scores,and inci-dence of adverse reactions.[Results]The clinical remission rate of the observation group(55.56％)was higher than that of the control group(33.33％)(P＜0.05).After treatment,the levels of serum carbohydrate antigen 125(CA125),squamous cell carcinoma antigen(SCC),and transforming growth factor beta 1(TGF-β1)decreased in both groups(P＜0.05),and the above indicators in the observation group were lower than those in the control group(P＜0.05).After treatment,the observation group had higher levels of CD3+and CD4+than the control group(P＜0.05),and lower levels of CD8+than the control group(P＜0.05).After treatment,the FACT-G scores of both groups of cancer treat-ment function evaluation scales increased(P＜0.05),and the FACT-G score of the observation group was higher than that of the control group(P＜0.05).There was no statistically significant difference in the total incidence of adverse re-actions between the two groups(P＞0.05).[Conclusion]The combination of bevacizumab and TP based synchronous chemoradiotherapy is effective in treating cervical cancer patients,improving their immune function and quality of life,re-ducing tumor markers and TGF-β1 expression levels,and has good safety.It is worthy of clinical application.
万方数据
